Takeda Pharmaceutical Company Limited (TKPHF.PK) and AC Immune SA (ACIU) Monday said they have signed license agreement for Immune's active immunotherapies including ACI-24.060 for the treatment of Alzheimer's disease.
As per the terms of the agreement, Takeda will receive an exclusive option to license global rights to ACI-24.060, designed to delay or slow Alzheimer's disease progression.
AC Immune will receive an upfront payment of $100 million and be eligible to receive an option exercise fee and additional milestone payments of up to about $2.1 billion. Upon commercialization, AC Immune will be entitled to receive tiered double-digit royalties on sales.
ACI-24.060 is currently being investigated in the ABATE Phase 1b/2 trial in subjects with prodromal Alzheimer's disease and in adults with Down syndrome. After completing ABATE trial by AC Immune, Takeda would conduct further clinical developments of ACI-24.060. Takeda would also be responsible for all global regulatory activities as well as worldwide commercialization.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.